| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Bon Natural Life Limited
$1.11
-0.04 (-3.45%)
Market Cap
6.76 M
EPS
-0.23
P/E Ratio
-
Value Trade
28.17 K
-0.87 %
Week
0.94 %
1 Month
-13.26 %
3 Month
-24.98 %
6 Month
-99.92 %
5 Year
-99.92 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
3.11 K
52 Week Range
1.05 - 2.34
% held by Insiders
26.59 %
% held by Institutions
0.49 %
Enterprise Value
16.79 M
Total Shares
6.09 M
Short %
0.27 %
Float Shares
6.09 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Bon Natural Life Limited
74Total events
0Upcoming
19Tier-1 (high impact)
2021 – 2026Coverage
Event history 2
TBD
▲Preclinical PoCPreclinical
Subscribe to view catalyst details
TBD
▲Partnership / LicenseCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in BON
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
BON Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
BONBON Unveils Strategic Partnership with Tigerbone Group to Launch New Natural Health Initiatives
Bon Natural Life Limited has announced a strategic partnership with Tigerbone Group to enhance collaboration in traditional Chinese medicine and life sciences. The agreement includes the formation of the 'BON Cooperation and Development Committee' to drive innovation and product development. This partnership aims to consolidate resources and leverage complementary strengths for global growth.
Read more →BONBON Announces Breakthrough Development of Apple Bio-Electronic Mask: Clinical Data Exceeds Expectations, Targeting $100B+ Medical Aesthetics Market
Bon Natural Life Limited has announced the successful development of a premium anti-aging bio-electronic facial mask using apple polyphenols and advanced AI-enabled technology. Initial internal evaluations show that the mask exceeds performance benchmarks for skin appearance and firmness. The company is moving towards third-party clinical testing and plans to optimize large-scale manufacturing. With the anti-aging market exceeding $100 billion, BON aims to position itself as a leader in this emerging segment.
Read more →BONBON Partners with Chang'an Pilot to Launch World-Class Joint Laboratory for Natural Ingredient Bio-manufacturing Bon Natural Life Limited (Nasdaq: BON) ("BON"or the "Company"), a leading bio-ingredient provider for the natural health and personal care...
Bon Natural Life Limited has launched the BON & Pilot Joint Laboratory for Natural Ingredients and Bio-Manufacturing in collaboration with Chang'an Pilot. This facility aims to enhance the research and development of bio-manufactured natural ingredients for functional foods and personal care products. The initiative is expected to improve production efficiency and sustainability through innovative technologies.
Read more →BONBON Partners with Chang'an Pilot to Launch World-Class Joint Laboratory for Natural Ingredient Bio-manufacturing XI'AN, China
Bon Natural Life Limited has partnered with Chang'an Pilot to launch a Joint Laboratory for Natural Ingredients and Bio-Manufacturing in Xi'an, China, as announced on February 17, 2026. This collaboration aims to enhance research and development of bio-manufactured natural ingredients for functional foods and personal care products. The laboratory will utilize fermentation-based biosynthesis and artificial intelligence to optimize production processes, providing a more sustainable alternative to traditional methods. The partnership is expected to advance BON's growth strategy and improve production efficiency.
Read more →BON▲ +8.2%on this news
BON Unveils Kombucha-Inspired Product, Inks $12 Million Strategic Sales Agreement with Qingshengyuan
Bon Natural Life Limited has launched a new kombucha-inspired beverage and entered a $12 million strategic sales agreement with Shaanxi Qingshengyuan Health Industry Co., Ltd. The partnership aims to distribute BON's tea-pigment products across Greater China over the next 24 months. This move aligns with the growing consumer interest in natural ingredients and functional beverages.
Read more →BONBON Announced Next-Gen of Tea Pigment Digestive Health Products and Cooperation Agreement of US$26 Million with Beijing Huahai Keyuan
Bon Natural Life Limited has announced a cooperation agreement with Beijing Huahai Keyuan for the distribution of its second-generation tea pigment-based digestive health products in Greater China. The agreement, valued at US$26 million over 36 months, aims to leverage the growing demand for digestive wellness and blood-glucose management. BON's innovative tea pigments have shown significant improvements in health benefits, positioning the company for growth in the premium digestive health market.
Read more →BONBON NATURAL LIFE LIMITED AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) As of
BON Natural Life Limited released its condensed consolidated balance sheets for the period ending March 31, 2025. The company reported total assets of $71.58 million, reflecting a growth from $61.77 million at the end of the previous period. Notably, net income attributable to the company improved compared to the prior period. However, the company also faced a comprehensive loss, showcasing challenges in profitability despite asset growth.
Read more →BON▼ -36.1%on this news
BON Announces $18 Million Cooperation Agreement for Innovative Second-Generation Apple Series Health Products
Bon Natural Life Limited has announced a non-exclusive cooperation agreement worth $18 million with Beijing Huahai Keyuan Technology to distribute its innovative second-generation Apple Series health products in Greater China. This new product line boasts 80% higher bioactivity and aims to meet the growing demand in weight management and metabolic health. The company is optimistic about its market performance and potential revenue growth.
Read more →BONBON Announces Identification of Promising Weight-Managing Compounds from Tea via AI-Powered New Drug R&D Platform
Bon Natural Life Limited has announced the identification of natural polyphenolic compounds from tea that show promise in weight management through its AI-powered R&D platform. Preliminary tests indicate these compounds outperform existing weight-managing drugs. With the global obesity crisis driving market growth, BON aims to capture a significant share of the weight management therapeutics market.
Read more →BONBON Announces Reciept of Nasdaq Compliance Letter
Bon Natural Life Limited has announced that it has regained compliance with Nasdaq's Listing Rule 5550(a)(2). The Nasdaq Hearings Panel confirmed this decision, and the compliance matter is now closed. The company will be subject to a one-year Discretionary Panel Monitor, ensuring ongoing compliance oversight.
Read more →BONBON Launches AI-Powered New Drug Research and Development
Bon Natural Life Limited has launched an AI-driven drug research and development business, leveraging its library of natural compounds, particularly from Traditional Chinese Medicine. This initiative aims to enhance the efficiency and success rate of drug discovery by identifying promising lead compounds. CEO Yongwei Hu expressed optimism about achieving breakthroughs in pharmaceutical research through this strategic evolution.
Read more →BON▼ -6%on this news
BON Announces $22 Million Distribution Agreement for Weight Loss Products with Beijing Huahai Keyuan Technology Co., Ltd
Bon Natural Life Limited has announced a $22 million distribution agreement with Beijing Huahai Keyuan Technology Co. Ltd. for its weight loss products. This non-exclusive agreement spans 36 months and allows Huahai Keyuan to distribute BON's innovative weight management line across China and Southeast Asia. The products are designed to facilitate weight management without requiring significant lifestyle changes.
Read more →BONBON Announces Nasdaq Compliance
Bon Natural Life Limited has announced that it has regained compliance with Nasdaq's continued listing requirements. The company received formal notice from the Nasdaq Hearings Panel confirming it met the Minimum Bid Price Requirement. BON will remain under a Discretionary Panel Monitor for one year to ensure ongoing compliance.
Read more →BON▲ +18.7%on this news
Bon Announces Breakthrough Order for $16 Million Gut-Health Products
Bon Natural Life Limited has announced a $16 million distribution agreement with Beijing Huahai Keyuan Technology to market its new prebiotic products in China. This partnership is expected to enhance Bon's presence in the growing gut health market. The innovative product series features a unique 'Prebiotic + Postbiotic' complex aimed at improving gut microbiota health.
Read more →BONBon Natural Life Announces Distribution Agreement with Tianjin Merrill-Youli Trading Co., Ltd.
Bon Natural Life Limited has announced a non-exclusive distribution agreement with Tianjin Merrill-Youli Trading Co., Ltd. The agreement, valued at up to $18 million over 36 months, will see Merrill-Youli market and distribute Bon's Ambroxide and related fragrance compounds in the Asia-Pacific region. The partnership aims to strengthen Bon's position in the fragrance market, particularly in fabric applications, while also advancing the development of a biosynthetic alternative to Sclareol.
Read more →BON▲ +6.9%on this news· ran to +22% by day 1
BON Announces Share Repurchase Program for up to US$1.0 Million
Bon Natural Life Limited has announced a share repurchase program allowing for the purchase of up to $1.0 million of its Class A ordinary shares. The program's execution will depend on various factors including market conditions and corporate liquidity. TradeUp Securities has been appointed as the exclusive agent for the repurchase. This initiative reflects the company's confidence in its financial stability.
Read more →BON▲ +50%on this news
BON Announces Launch of Tea Pigment Digestive Health Products and Cooperation Agreement Signed with Shanghai Risesun International Trade
Bon Natural Life Limited has announced a sales cooperation agreement with Shanghai Risesun International Trade to market its tea pigment health products in China. The agreement, valued at $24 million over 24 months, aims to tap into the growing demand for digestive wellness and blood glucose regulation. CEO Hu Yongwei emphasized the partnership's potential to accelerate revenue growth and expand BON's market presence.
Read more →BON▲ +22.5%on this news
BON Announces The Launch Of Its Postbiotic Hypoglycemic Patented Ingredient Product Series And Its Cooperation Agreement
Bon Natural Life Limited (BON) has announced the launch of its patented postbiotic hypoglycemic ingredient product series and an exclusive cooperation agreement with Beijing Huahai Keyuan. The agreement, valued at 32 million USD, aims to enhance BON's presence in the global blood sugar health market. The new ingredient is designed to effectively regulate blood sugar levels, offering safety and convenience for users.
Read more →BON▼ -13.2%on this newsshared move
Bon Natural Life Limited Announces Effectiveness of Reverse Stock Split
Bon Natural Life Limited announced a 1-for-25 reverse stock split effective May 19, 2025, to comply with Nasdaq's minimum bid price requirement. The split will not affect shareholders' percentage interests. The company also increased its authorized share capital and adjusted the conversion rate for Class B shares. This decision was approved by shareholders at an extraordinary general meeting.
Read more →BON▼ -8.9%on this newsshared move
BON Debuts Groundbreaking Broccoli-Derived Sleep Wellness Line, Reshaping the Sleep Health Market through Innovative Technology
BON Natural Life Limited has launched a new sleep health product line utilizing a patent-pending delivery system called 'Glucoraphanin-Myrosinase'. This innovative technology aims to enhance the absorption and effectiveness of glucoraphanin, a compound found in broccoli. The company anticipates that these products will address unmet needs in sleep health and lead to significant market expansion.
Read more →BON▼ -19.1%on this news
Bon Natural Life Limited Announces Receipt of Nasdaq Delisting Notifications
Bon Natural Life Limited has received notifications from Nasdaq regarding delisting due to non-compliance with the Minimum Bid Price Requirement. The company's Class A ordinary shares have been trading below the required price for over 30 days, and additional concerns have arisen from a recent offering. The company has filed an appeal to contest the delisting decision, but there are no guarantees of success.
Read more →BON▲ +16.5%on this news
BON Announces Apple Polyphenol Commercial Order Signed
Bon Natural Life Limited has signed a significant 24-month supply agreement worth $12 million with Shanghai Yunsheng to develop apple polyphenol-infused health solutions. This partnership aims to leverage BON's patented extraction technology to create formulations that support weight management and metabolic health. The market shows promising validation, with similar products achieving substantial sales and revenue.
Read more →BONBON Announces Unlocking Broccoli's Nutritional Power: Advanced Delivery System for Glucoraphanin Activation
Bon Natural Life Limited has announced a patent-pending Glucoraphanin-Myrosinase co-delivery system that enhances the bio-activity of glucoraphanin, a key compound in broccoli. This innovation aims to improve the conversion efficiency of glucoraphanin to sulforaphane, which has various health benefits. The technology is expected to enter the market in Q2 2025, with significant potential in the wellness market.
Read more →BON▲ +6.2%on this newsshared move
BON Announces Breakthrough in the Bio-manufacturing Technology of Tea Pigments
Bon Natural Life Limited has made significant advancements in the bio-manufacturing of tea pigments, achieving yield rates of 12-16% and purity levels over 95%. The tea pigments show promising health benefits, including lipid-lowering and antioxidant effects, and are expected to drive growth in the digestive wellness and blood glucose sectors. The global market for tea pigments is projected to surpass $12 billion by 2025.
Read more →BON▼ -8.2%on this news· ran to -36% by day 3
Bon Natural Life Limited Registered Company No 358246 (the Company ) NOTICE OF EXTRAODINARY GENERAL MEETING Notice is hereby given that the extraordinary general meeting (the Meeting ) of Bon Natural Life Limited, a Caym
Bon Natural Life Limited has called an extraordinary general meeting on April 15, 2025, to discuss significant corporate resolutions. Key proposals include a share consolidation that would alter the authorized share capital structure, impacting the voting power distribution among shareholders. Class A ordinary shares will drastically reduce their voting influence to 1%, while Class B shares will control 99%. The meeting will also address the adoption of a new memorandum and articles of association.
Read more →BON▼ -57.5%on this news· ran to -82% by day 3
Bon Natural Life Limited Announces Pricing of $12 Million Best Efforts Offering XI'AN, China
Bon Natural Life Limited has announced a successful pricing of a $12 million best efforts offering aimed at funding its sales network expansion, research and development, and production capacity. This offering includes shares and warrants to be exercised at specified prices. The company plans to close the offering on or about March 18, 2025, subject to customary conditions. Despite the positive funding news, the company faces risks related to its limited operational history and ability to raise future capital.
Read more →BONBon Natural Life Limited Registered Company No 358246 (the Company) NOTICE OF EXTRAODINARY GENERAL MEETING Notice is hereby given that the extraordinary general meeting (the Meeting ) of Bon Natural Life Limited, a Cayma
Bon Natural Life Limited is convening an extraordinary general meeting on January 16, 2025, to discuss several proposals including a share capital reorganization and amendments to the company's memorandum and articles of association. Key points of discussion will include the re-designation of existing shares into Class A Ordinary Shares and the creation of Class B Ordinary Shares. The meeting is open to shareholders who are registered by December 25, 2024, and they may appoint proxies to vote on their behalf.
Read more →BONBon Natural Life Limited Announces Brand Strategic Cooperation with Guangdong JUWO XI'AN, China
Bon Natural Life Limited announced a strategic cooperation agreement with Guangdong JUWO to develop a marketing and supply chain system for liquor distribution in China. Under this agreement, JUWO will co-brand alcoholic health products with BON's App-Chem brand and handle their marketing. The partnership aims to merge traditional Chinese culture with bio-tech innovations in liquor production. Yongwei Hu, the CEO, expressed optimism about the potential market growth and enhanced competitiveness this collaboration brings.
Read more →BON▼ -8.5%on this news
Bon Natural Life Limited Announces Major Breakthrough in Apple Polyphenol Technology, Set to Boost Fiscal 2024 Sales
Bon Natural Life Limited has announced a major breakthrough in apple polyphenol extraction technology, which is anticipated to drive growth in its product sales for fiscal 2024. This innovation addresses previous challenges related to chemical instability and high production costs. With a current production capacity of 300 to 500 tons, the company expects significant progress in the dietary supplements and personal care markets. The CEO highlighted the potential of apple polyphenols as a key driver for sustainable growth and a transformative force in the industry.
Read more →BON▼ -10.9%on this news
Bon Natural Life Limited Announces $45 Million Broccoli Product Order with Beijing Huahai Keyuan
Bon Natural Life Limited has announced a $45 million sales distributing contract with Beijing Huahai Keyuan Technology. This agreement grants Huahai priority rights to market Bon's Broclife® product in China, which highlights the company's strategy to improve its presence in the health sector. The Broclife® product, developed from broccoli seed extracts, is touted for its health benefits including immunity support and anti-inflammatory properties. The collaboration is expected to enhance Bon's market penetration and drive significant sales growth.
Read more →BONBon Natural Life Limited Incentive Compensation Recovery Policy Effective Date
Bon Natural Life Limited has implemented an Incentive Compensation Recovery Policy effective November 22, 2023. This policy is designed to recover any erroneously awarded incentive-based compensation in the event of an accounting restatement, ensuring compliance with Section 10D of the Securities Exchange Act and Nasdaq Listing Standards. It applies to compensation received by executive officers since October 2, 2023, and allows for flexible recovery methods as determined by the Compensation Committee.
Read more →BONBon Natural Life Limited Announces Signing MOU for Distributing Jiangwang Spirits in China
Bon Natural Life Limited has signed a Memorandum of Understanding with Guangdong Jiangwang International Holdings Limited to negotiate the distribution of Jiangwang's Chinese White Spirits and related health products in China. This marks BON's entry into the spirits sector after 16 years in the health and personal care industries. Both companies express optimism about leveraging their strengths for mutual development and enhancing market presence. The collaboration may also pave the way for innovative healthy spirit products under BON's brand.
Read more →BON▲ +5.2%on this newsshared move
Memorandum of Understanding Bon Natural Life Limited NASDAQ: BON "BON" Party A Bon Natural Life Limited NASDAQ: BON ("BON") " " Party B: Guangdong Jiangwang International Holdings Limited ("Jiangwang") BON 2021 6 BON, ge
Bon Natural Life Limited (BON) has entered a Memorandum of Understanding with Guangdong Jiangwang International Holdings Limited to distribute Jiangwang Spirits and related health products in China. This collaboration is aimed at tapping into the growing spirit market in the region. BON, known for its natural active ingredients in functional foods, is now seeking to expand its product offerings to include spirit-related health products. The companies plan to finalize the distribution agreement in the near future, although further details cannot be disclosed at this time.
Read more →BON▼ -9.4%on this news
Bon Natural Life Limited Announces Record First Half-Year Revenue and Net Income
Bon Natural Life Limited reported a record revenue of $14.1 million for the first half of 2023, reflecting a 3.4% increase from the previous year. Although income from operations rose by 7.1%, net income decreased to $2.1 million, down from $2.5 million last year. The company experienced notable revenue growth in health supplements, while the revenue from fragrance compounds saw a decline. Increased general and administrative costs raised some concerns about future profitability amidst the positive sales trends.
Read more →BONBon Natural Life Limited Receives NASDAQ Notification Regarding Independent Board Requirement
Bon Natural Life Limited received a Notification Letter from Nasdaq informing them of non-compliance with majority independent board requirements following the resignations of three board members. The company has until August 14, 2023, to submit a plan to regain compliance, which may result in an extension of up to 180 days. Bon Natural Life is currently working to identify and retain new independent directors to address these governance issues.
Read more →BONBon Natural Life Limited Receives NASDAQ Notification Regarding Minimum Bid Deficiency
Bon Natural Life Limited has received a notification from Nasdaq stating it is not in compliance with the minimum bid price requirement. The company's ordinary shares have been below $1.00 for more than 30 consecutive business days. They have until December 11, 2023, to regain compliance by achieving a closing bid price of at least $1.00 for 10 consecutive business days. Failure to do so may result in additional compliance time or potential delisting.
Read more →BON▼ -5.1%on this news
Bon Natural Life Limited Launches Three New Cruciferous Vegetable-Based Powder Drinks
Bon Natural Life Limited has announced the launch of three new powder drinks based on cruciferous vegetables, including broccoli seed variations. These drinks aim to enhance microbiome health and immune function through a proprietary formulation that includes broccoli seed extract and stachyose. The CEO, Richard (Yongwei) Hu, emphasized the company's optimistic outlook on market opportunities driven by increasing health awareness among consumers in China. This initiative marks a significant step in BON's expansion into the consumer market for health supplements.
Read more →BON▲ +6.1%on this news
Bon Natural Life Limited Voted as Vice Chairman Unit of Plant Extract Association
Bon Natural Life Limited has been elected as the Vice Chairman Unit of the Plant Extract Association by the China Chamber of Commerce for Import & Export of Medicines & Health Products. Chairman and CEO, Mr. Yongwei Hu, expressed pride in this recognition, highlighting the company's dedication to delivering high-quality products. This leadership role is expected to enhance BON's industry standing and facilitate their global market expansion, indicating potential for future growth.
Read more →BONBon Natural Life Limited Appoints Wallace Lee as New Chief Financial Officer
Bon Natural Life Limited has appointed Wallace Lee as its new Chief Financial Officer, effective April 17, 2023. Lee, a seasoned finance professional with over 16 years of experience, succeeds Zhenchao Li, who held the position for four years. Company officials expressed confidence in Lee's ability to lead financial operations and support the firm's growth strategies. His background includes pivotal roles in finance for various companies, enhancing expectations for BON's future direction.
Read more →BONBon Natural Life Limited Announces Record-Setting Full Fiscal Year 2022 Results
Bon Natural Life Limited announced record-setting financial results for FY 2022, reporting a 17.3% increase in revenue to $29.9 million and a 35.4% rise in net income to $6.2 million. The company noted significant growth in their bioactive food ingredients, with revenues increasing by 48.5%. Despite these successes, they faced challenges like inflation and supply chain disruptions impacting sales volume in some product categories. Looking forward, the completion of the Yumen Plant is expected to drive substantial revenue growth.
Read more →BONBon Natural Life Limited Announces FY2022 Earnings Release Date and Webcast
Bon Natural Life Limited plans to release its FY2022 earnings on February 10, 2023, before the market opens. An investor conference call and webcast will be held that same day at 9:00 a.m. EST, featuring key management members. Investors will have multiple options to participate, including a live webcast and a dial-in number. The company focuses on manufacturing personal care ingredients and health supplements.
Read more →BONBon Natural Life Limited Provides Update on Its Expansion Project
Bon Natural Life Limited has announced a delay in the production target for its Yumen Plant, moving it from Q4 2022 to May 2023. The delay is attributed to COVID-19 control measures, logistical disruptions, and labor shortages. Despite these challenges, the company remains optimistic about the plant's potential for producing fragrance compounds and bioactive food ingredients.
Read more →BONBON NATURAL LIFE LIMITED AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
BON NATURAL LIFE LIMITED us-gaap:CommonStockMember us-gaap:AdditionalPaidInCapitalMember BON:StatutoryReserveMember us-gaap:RetainedEarningsMember us-gaap:AccumulatedOtherComprehensiveIncomeMember BON:TotalShareholdersEquityMember us-gaap:NoncontrollingInterestMember us-g
Read more →BONBon Natural Life Limited Announces 2022 Half-Year Earnings Release Date and Webcast
Earnings to be released before market opens on Monday, August 1, 2022 XIAN, China, July 28, 2022 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care indust
Read more →BONBon Natural Life Limited Announces Change to Board Composition Xian, China
Natural Life Limited Announces Change to Board Composition China, June 30, 2022 - Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, today announced the appo
Read more →BONBon Natural Life Limited Introduces New Powder Drink For Anti-H. Pylori and Digestive Health
XI'AN, China, June 16, 2022 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, today announced that it has launched a new cruciferous vegetable
Read more →BONBon Natural Life Limited Advances Towards Near Term Production and Completes Building Construction of Yumen Plant
HIGHLIGHTS OF A TRANSFORMATIVE 2022 Yumen Plant commissioning is on schedule and forecasted to commence around September 2022 to deliver near term production of fragrance compounds and bioactive food ingredients. A 200% increase in production capacity in these two product categ
Read more →BONBon Natural Life Limited Adds New Multi-Functional Health Supplements to Product Line
XI'AN, China, April 21, 2022 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, today announced that it has successfully developed new nutraceu
Read more →BONBon Natural Life Bon Natural Life Limited Announces Record-Setting Full Fiscal Year 2021 Results - Revenue increased by 39.9% to $25.49 million. - Delivered full fiscal year 2021 net income of $4.6 million, or $0.68 per
Natural Life Limited Announces Record-Setting Full Fiscal Year 2021 Results China, February 2, 2021 - Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, toda
Read more →BONBon Natural Life Limited Announces Record-Setting Full Fiscal Year 2021 Results
XI'AN, China, Feb. 2, 2022 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, today announced its 2021 annual financial results for the fiscal
Read more →BONBon Natural Life Limited Announces FY2021 Earnings Release Date and Webcast Earnings to be released before market opens on Monday
Natural Life Limited Announces FY2021 Earnings Release Date and Webcast China, January 28, 2022 - Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, will iss
Read more →BONBon Natural Life Limited Announces FY2021 Earnings Release Date and Webcast
Earnings to be released before market opens on Monday, January 31, 2022 XI'AN, China, Jan. 28, 2022 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care ind
Read more →BONBon Natural Life Limited Received Initial Purchase Order for its Stachyose and Apple Extract based Personal Care Products
XIAN, China, Jan. 12, 2022 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, today announced that it has received an initial purchase order (t
Read more →BONBon Natural Life Limited Announces Corporate Reorganization and Removal of VIE Structure
XI'AN, China, Nov. 9, 2021 /PRNewswire/-- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, today announced it has removed its variable interest entity ("VIE"
Read more →BONBon Natural Life Limited Announces Strategic Cooperation with Chongqing Jingfubao to Penetrate Consumer Market
XI'AN, China, Sept. 9, 2021 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, today announced that its principle operating entity has entered
Read more →BONBon Natural Life Limited Announces 2021 Half-Year Earnings Release Date and Webcast
Earnings to be released before market opens on Tuesday, August 17, 2021 XIAN, China, Aug. 12, 2021 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care indu
Read more →BONBon Natural Life Limited Breaks Ground on Its Third Production Facility in Yumen
XIAN, China, July 29, 2021 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), a leading bio-ingredient solutions provider in the natural, health and personal care industries, officially broke ground today on its third production facility in Yumen Cit
Read more →BONBon Natural Life Limited Announces Land Acquisition to Construct Its Third Production Facility Key Milestone To Increase Production Capacity Xian, China
Natural Life Limited Announces Land Acquisition to Construct Its Third Production Facility Milestone To Increase Production Capacity China, July 6, 2021 - Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), a leading bio-ingredient solutions provider in the natura
Read more →BONBon Natural Life Limited Announces Full Exercise of the Underwriter’s Over-Allotment Option
Xian, China, July 02, 2021 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, today announced the issuance and sale of an additional 330,00
Read more →BONBon Natural Life Limited Announces Closing of Upsized $11 Million Initial Public Offering
Xian, China, June 28, 2021 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, today announced the closing of its previously announced firm
Read more →BONBon Natural Life Limited Announces Pricing of Upsized $11 Million Initial Public Offering Xian, China
Natural Life Limited Announces Pricing of Upsized $11 Million Initial Public Offering China, June 23, 2021 - Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industrie
Read more →Competitive Position
How BON ranks across every disease it competes inCompetitive Position is a premium feature
See how BON ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial